Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.

Studied

T-BEAT is an ongoing observational comparison of tirzepatide and oral semaglutide in early type 2 diabetes in Japan. The primary outcome is average blood-sugar change over up to 12 months.

Who / model

Baseline data cover 290 people receiving tirzepatide and 279 receiving oral semaglutide. Participants previously used diet and exercise alone or one oral diabetes medicine.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

This report describes starting characteristics, including average HbA1c of 8.0% with tirzepatide and 7.8% with oral semaglutide. These are baseline blood-sugar measurements, not treatment responses.

Limits

The study was still in progress; comparative effectiveness results were not yet presented.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary